Apart from their role in CRPC, glucocorticoids can also contribute to treatment failure in many other cancer types.[45,46] Understanding the tumorigenic effects of GR activation in other tumor types might provide useful insights and generate interesting hypotheses regarding the effects of GR in prostate cancer. This evidence concerns the gene NR3C1 and prostate cancer.